Navigation Links
QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
Date:5/4/2010

f them in light of new information or future events.

By their very nature, forward-looking statements involve risks and uncertainties.  A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement.  Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to directly commercialize its products in the US and seek strategic partnerships for worldwide markets.  QRxPharma's lead product candidate, MoxDuo®IR, is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equianalgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain.  Data collected from these studies provided additional guidance for optimizing the design and initiation of two pivotal Phase 3 studies required for New Drug Application (NDA) filings with the US Food and Drug Administration (FDA).  QRxPharma expects to complete its Phase 3 program Q3 CY2010 and file its NDA for MoxDuo®IR in Q4 CY2010.  The Company's preclinic
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
4. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
5. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
6. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
9. BetterInvesting Magazine Releases Julys Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
10. QRS Diagnostic Releases 64-bit and Windows(R) 7 Compatible Software
11. BioVigil Releases Second-Generation Hand Hygiene Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
(Date:1/22/2015)... Corporation (NASDAQ: TECH ) announced today that ... new Simple Plex platform through its Proteins Platform division ... of the previously acquired CyPlex instrument platform from CyVek. ... immunoassay technology which integrates an innovatively designed microfluidic cartridge ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... January 22, 2015 The federal court overseeing ... U.S. District Court, Southern District of West Virginia has upheld ... that proceeding’s first bellwether trial. In an Order dated January ... trial after finding that C.R. Bard had not proven a ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... , FRIDAY, Sept. 9 (HealthDay News) -- Good hygiene ... bacterial and viral infections, according to the U.S. Centers ... growing concern that strict adherence to good hygiene, though ... open to other forms of illness. Proponents of ...
... -- More than one-half of all adverse drug reactions ... to a new study. In addition, prior research ... include drug overdoses and internal bleeding associated with the ... life-threatening, said the Swedish researchers. This widespread problem, which ...
... News) -- Having control over how to communicate with ... patients cope with their situation, according to a new ... Austin interviewed cancer survivors about strategies they used in ... about their condition, challenges they faced, advice they received, ...
... finds that lung cancer patients treated in hospitals ... and Medicaid-insured patients, so-called "high safety-net burden facilities," ... was intended to cure the cancer compared to ... difference persisted even after controlling for other factors ...
... Reinberg HealthDay Reporter , FRIDAY, Sept. 9 ... and Drug Administration were to meet Friday to discuss ... as Fosamax, Actonel, Boniva and Reclast. These ... related to postmenopausal osteoporosis. But researchers have linked long-term ...
... vaccine Cervarix may be just as effective as the standard ... cancer, according to a new study published September 9 in ... Across the globe, cervical cancer is the third most ... are a large contributor to the development of the disease. ...
Cached Medicine News:Health News:A Little Dirt May Be a Good Thing 2Health News:A Little Dirt May Be a Good Thing 3Health News:Over Half of Adverse Drug Reactions in Hospitals Are Preventable: Study 2Health News:Talking -- or Not Talking -- Can Give Cancer Patients a Sense of Control 2Health News:Study finds hospitals of last resort deliver lower quality of lung cancer care 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 2Health News:Osteoporosis Drugs' Safety Subject of FDA Panel 3Health News:Fewer than 3 doses of cervical cancer vaccine effective 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: